Here we challenged mice with poorly immunogenic 4T1 breast tumour cells and tested whether treatment with anti-CD5 monoclonal antibodies (MAb) <i>in vivo</i> could enhance non-malignant T cell anti-tumour immunity and reduce tumour growth. This evidence concerns the gene CD5 and neoplasm.